Dwight King, MD
Psychiatry · Washington, DCNPI 1679574313
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 625 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,573, 3.7 times the $971 reported in 2022. Among psychiatry clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 625 payments — averaging $16.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$1K
- Alkermes, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$887
- AbbVie$843
- Neurocrine Biosciences, Inc.$818
- Vanda Pharmaceuticals Inc.$702
- plus $4K from 17 others
What the payments were for
- Food & beverage$10,084100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 141 | $1,478 |
| Alkermes, Inc. | 51 | $1,019 |
| Otsuka America Pharmaceutical, Inc. | 56 | $887 |
| AbbVie | 72 | $843 |
| Neurocrine Biosciences, Inc. | 42 | $818 |
| Vanda Pharmaceuticals Inc. | 24 | $702 |
| Axsome Therapeutics, Inc. | 33 | $660 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 32 | $603 |
| Johnson & Johnson | 28 | $485 |
| E.r. Squibb & Sons, L.L.C. | 17 | $408 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $375 |
| Lundbeck LLC | 17 | $368 |
| Corium, LLC | 22 | $346 |
| Teva Pharmaceuticals USA, Inc. | 16 | $301 |
| Bausch Health US, LLC | 14 | $233 |
| Idorsia Pharmaceuticals US Inc | 12 | $166 |
| Noven Therapeutics, LLC | 7 | $136 |
| Sunovion Pharmaceuticals Inc. | 4 | $67 |
| Neos Therapeutics, LP | 4 | $62 |
| Ironshore Pharmaceuticals Inc. | 2 | $45 |
| Collegium Pharmaceutical, Inc. | 2 | $29 |
| Indivior Inc. | 2 | $29 |
| Luye Pharma (USA) Ltd. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,084 in reported general payments places this provider in the 95th percentile of 226 psychiatry providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 14 | $111,619 |
| RexultiBrexpiprazole | 39 | $69,102 |
| Invega SustennaPaliperidone Palmitate | 18 | $55,240 |
| CaplytaLumateperone Tosylate | 26 | $41,507 |
| TrintellixVortioxetine Hydrobromide | 34 | $23,780 |
| VraylarCariprazine Hcl | 12 | $20,116 |
| Lamotrigine OdtLamotrigine | 18 | $8,363 |
| Aripiprazole | 73 | $5,264 |
| Clozapine | 57 | $4,597 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 31 | $3,555 |
| Lisdexamfetamine Dimesylate | 18 | $2,895 |
| Quetiapine Fumarate | 109 | $2,022 |
| Olanzapine | 94 | $1,637 |
| Bupropion XlBupropion Hcl | 71 | $1,581 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 72 | $1,518 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $818 | $111,61914 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $887 | $69,10239 claims |
| Johnson & JohnsonInvega Sustenna | $485 | $55,24018 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $603 | $41,50726 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $375 | $23,78034 claims |
| AbbVieVraylar | $843 | $20,11612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 226 psychiatry providers in District of Columbia.
Other psychiatry in Washington
- Ikechi NnawuchiWashington$624K
- James GordonWashington$20K
- Thomas MellmanWashington$19K
- Tony GoreWashington$11K
- Igor VolkovWashington$10K
- Joel KleinmanWashington$8K
- Vivienne GomesWashington$6K
- Irfan SaeedWashington$6K
- Arda KasaciWashington$5K
- Todd AugustusWashington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.